Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice

Molecular Genetics and Metabolism

Volumn 115, Issue 1, 2015, Pages 33-40

  Beard, Helen ^a   Luck, Amanda J ^a   Hassiotis, Sofia ^a   King, Barbara ^a   Trim, Paul J ^a   Snel, Marten F ^a   Hopwood, John J ^a   Hemsley, Kim M ^a  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Cerebrospinal fluid; Enzyme replacement therapy; Lysosomal storage disorder; Mouse; MPS IIIA; Sanfilippo syndrome

Indexed keywords

HEPARAN SULFATE; LYSOSOMAL INTEGRAL MEMBRANE PROTEIN 2; MEMBRANE PROTEIN; RECOMBINANT ENZYME; RECOMBINANT HUMAN SULFAMIDASE; UNCLASSIFIED DRUG; HYDROLASE; N-SULFOGLUCOSAMINE SULFOHYDROLASE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN CORTEX; BRAIN STEM; CEREBELLUM; CISTERNA MAGNA; CONTROLLED STUDY; DENTATE GYRUS; DRUG DISTRIBUTION; DURA MATER; ENZYME REPLACEMENT; EPENDYMA CELL; GLIOSIS; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFERIOR COLLICULUS; INJECTION SITE; LATERAL BRAIN VENTRICLE; LUMBAR SPINAL CORD; MENINX; MOUSE; NONHUMAN; OLFACTORY BULB; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; SANFILIPPO SYNDROME; TREATMENT RESPONSE; ANIMAL; BRAIN; C57BL MOUSE; CEREBROSPINAL FLUID; CONGENIC STRAIN; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; GENETICS; HUMAN; INJECTION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; MUCOPOLYSACCHARIDOSIS III; PATHOLOGY; PROCEDURES;

ANIMALIA; MUS;

ANIMALS; BRAIN; CISTERNA MAGNA; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; ENZYME REPLACEMENT THERAPY; HEPARITIN SULFATE; HUMANS; HYDROLASES; INFUSIONS, INTRAVENTRICULAR; INFUSIONS, SPINAL; INJECTIONS; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MUCOPOLYSACCHARIDOSIS III; RECOMBINANT PROTEINS;

EID: 84933678072     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2015.03.002     Document Type: Article

References (42)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York 2001, 3421-3452. C.R. Scriver, A.L. Beaudet, D./. Valle, W.S. Sly (Eds.).
2. Valstar M.J., Neijs S., Bruggenwirth H.T., Olmer R., Ruijter G.J., Wevers R.A., van Diggelen O.P., Poorthuis B.J., Halley D.J., Wijburg F.A. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann. Neurol. 2010, 68:876-887.
3. Tardieu M., Zérah M., Husson B., de Bournonville S., Deiva K., Adamsbaum C., Vincent F., Hocquemiller M., Broissand C., Furlan V., Ballabio A., Fraldi A., Crystal R.G., Baugnon T., Roujeau T., Heard J.M., Danos O. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum. Gene Ther. 2014, 25:506-516.
4. Hemsley K.M., King B., Hopwood J.J. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol. Genet. Metab. 2007, 90:313-328.
5. Hemsley K.M., Beard H., King B.M., Hopwood J.J. Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav. 2008, 7:740-753.
6. Hemsley K.M., Luck A.J., Crawley A.C., Hassiotis S., Beard H., King B., Rozek T., Rozaklis T., Fuller M., Hopwood J.J. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur. J. Neurosci. 2009, 29:1197-1214.
7. Hemsley K.M., Norman E.J., Crawley A.C., Auclair D., King B., Fuller M., Lang D.L., Dean C.J., Jolly R.D., Hopwood J.J. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs-a proof of principle study. Mol. Genet. Metab. 2009, 98:383-392.
8. Crawley A.C., Marshall N., Beard H., Hassiotis S., Walsh V., King B., Hucker N., Fuller M., Jolly R.D., Hopwood J.J., Hemsley K.M. Enzyme replacement reduces neuropathology in MPS IIIA dogs. Neurobiol. Dis. 2011, 43:422-434.
9. Hassiotis S., Beard H., Luck A., Trim P., King B., Snel M., Hopwood J.J., Hemsley K.M. Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease. Eur. J. Neurosci. 2014, 39:2139-2150.
10. Marshall N.R., Hassiotis S., King B., Rozaklis T., Trim P.J., Duplock S.K., Winner L.K., Beard H., Snel M.F., Jolly R.D., Hopwood J.J., Hemsley K.M. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Exp. Neurol. 2015, 263:79-90.
11. King B., Marshall N., Beard H., Hassiotis S., Trim P.J., Snel M.F., Rozaklis T., Jolly R.D., Hopwood J.J., Hemsley K.M. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain. J. Inherit. Metab. Dis. 2015, (in press). 10.1007/s10545-014-9790-8.
12. Kakkis E., McEntee M., Vogler C., Le S., Levy B., Belichenko P., Mobley W., Dickson P., Hanson S., Passage M. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol. Genet. Metab. 2004, 83:163-174.
13. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.
14. Lee W.C., Tsoi Y.K., Troendle F.J., DeLucia M.W., Ahmed Z., Dicky C.A., Dickson D.W., Eckman C.B. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. F.A.S.E.B. J. 2007, 21:2520-2527.
15. Chang M., Cooper J.D., Sleat D.E., Cheng S.H., Dodge J.C., Passini M.A., Lobel P., Davidson B.L. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 2008, 16:649-656.
16. Katz M.L., Coates J.R., Sibigtroth C.M., Taylor J.D., Carpentier M., Young W.M., Wininger F.A., Kennedy D., Vuillemenot B.R., O'Neill C.A. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). J. Neurosci. Res. 2014, 92:1591-1598.
17. Dodge J.C., Clarke J., Treleaven C.M., Taksir T.V., Griffiths D.A., Yang W., Fidler J.A., Passini M.A., Karey K.P., Schuchman E.H., Cheng S.H., Shihabuddin L.S. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp. Neurol. 2009, 215:349-357.
18. Kondagari G.S., King B.M., Thomson P.C., Williamson P., Clements P.R., Fuller M., Hemsley K.M., Hopwood J.J., Taylor R.M. Treatment of canine fucosidosis by intracisternal enzyme infusion. Exp. Neurol. 2011, 230:218-226.
19. Stroobants S., Gerlach D., Matthes F., Hartmann D., Fogh J., Gieselmann V., D'Hooge R., Matzner U. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum. Mol. Genet. 2011, 20:2760-2769.
20. Calias P., Papisov M., Pan J., Savioli N., Belov V., Huang Y., Lotterhand J., Alessandrini M., Liu N., Fischman A.J., Powell J.L., Heartlein M.W. PLoS One 2012, 7(1):e30341.
21. Hemsley K.M., Hopwood J.J. Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality. J. Inherit. Metab. Dis. 2011, 34:1003-1012.
22. Wright B.L., Lai J.T., Sinclair A.J. Cerebrospinal fluid and lumbar puncture: a practical review. J. Neurol. 2014, 259:1530-1545.
23. McComb J.G. Recent research into the nature of cerebrospinal fluid formation and absorption. J. Neurosurg. 1983, 59:369-383.
24. Johnston M., Zakharov A., Papaiconomou C., Salmasi G., Armstrong D. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 2004, 1:2.
25. Jolly R.D., Marshall N.R., Perrott M.R., Dittmer K.E., Hemsley K.M., Beard H. Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain. Neuropathol. Appl. Neurobiol. 2011, 37:414-422.
26. Jolly R.D., Marshall N., Marshall J., Hartman A., Hemsley K., Winner L. Intracisternal enzyme replacement therapy in lysosomal storage diseases: dispersal pathways, regional enzyme concentrations and the effect of post-treatment posture. Neuropathol. Appl. Neurobiol. 2013, 39:681-692.
27. Crawley A.C., Gliddon B.L., Auclair D., Brodie S.L., Hirte C., King B.M., Fuller M., Hemsley K.M., Hopwood J.J. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res. 2006, 1104:1-17.
28. Gliddon B.L., Hopwood J.J. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr. Res. 2004, 56:65-72.
29. Bhattacharyya R., Gliddon B.L., Beccari T., Hopwood J.J., Stanley P. A novel missense mutation in lysosomal sulfamidase is the basis of MPS IIIA in a spontaneous mouse mutant. Glycobiology 2001, 11:99-103.
30. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Co-ordinates 2001, Academic Press, USA.
31. Hyldan J.L.K., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 1980, 67:313-316.
32. Trim P.J., Lau A.A., Hopwood J.J., Snel M.F. A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA. Rapid Commun. Mass Spectrom. 2014, 28:933-938.
33. Rozaklis T., Beard H., Hassiotis S., Garcia A.R., Tonini M., Luck A., Pan J., Lamsa J.C., Hopwood J.J., Hemsley K.M. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp. Neurol. 2011, 230:123-130.
34. Hsu Y., Hettiarachchi H.D., Zhu D.C., Linninger A.A. The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth. Analg. 2012, 115:386-394.
35. Sakka L., Coll G., Chazal J. Anatomy and physiology of cerebrospinal fluid. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2011, 128:309-316.
36. Pardridge W.M. Transnasal and intraventricular delivery of drugs. Peptide Drug Delivery to the Brain 1991, Raven Press, New York.
37. Oshio K., Watanabe H., Song Y., Verkman A.S., Manley G.T. Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1. FASEB J. 2005, 19:76-78.
38. Di Terlizzi R., Platt S. The function, composition and analysis of cerebrospinal fluid in companion animals: part I - function and composition. Vet. J. 2006, 172:422-431.
39. Cabrera-Salazar M.A., Bercury S.D., Ziegler R.J., Marshall J., Hodges B.L., Chuang W.L., Pacheco J., Li L., Cheng S.H., Scheule R.K. Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease. Exp. Neurol. 2010, 225:436-444.
40. M2 gangliosidosis. Ann. Neurol. 2010, 69:691-701.
41. Higuchi T., Shimizu H., Fukuda T., Kawagoe S., Matsumoto J., Shimada Y., Kobayashi H., Ida H., Ohashi T., Morimoto H., Hirato T., Nishino K., Eto Y. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Mol. Genet. Metab. 2012, 107:122-128.
42. Vuillemenot B.R., Kennedy D., Cooper J.D., Wong A.M., Sri S., Doeleman T., Katz M.L., Coates J.R., Johnson G.C., Reed R.P., Adams E.L., Butt M.T., Musson D.G., Henshaw J., Keve S., Cahayag R., Tsuruda L.S., O'Neill C.A. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 2014, 10.1016/j.ymgme.2014.09.004.